MP72-01 PHASE 1 OUTCOMES OF A NOVEL THIRD GENERATION LIPOSOMAL PACLITAXEL FORMULATION (TSD-001) IN LOW-INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS | Zendy

AI Assistant Blog Pricing

MP72-01 PHASE 1 OUTCOMES OF A NOVEL THIRD GENERATION LIPOSOMAL PACLITAXEL FORMULATION (TSD-001) IN LOW-INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.